دورية أكاديمية
أعرض في EDS

Acute rejection post lung transplant.

التفاصيل البيبلوغرافية
العنوان: Acute rejection post lung transplant.
المؤلفون: Hanks J; Department of Pulmonary Medicine, Integrated Hospital Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA., Girard C, Sehgal S
المصدر: Current opinion in pulmonary medicine [Curr Opin Pulm Med] 2024 Jul 01; Vol. 30 (4), pp. 391-397. Date of Electronic Publication: 2024 Apr 25.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9503765 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-6971 (Electronic) Linking ISSN: 10705287 NLM ISO Abbreviation: Curr Opin Pulm Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia, PA : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Current Science, c1995-
مواضيع طبية MeSH: Lung Transplantation*/adverse effects , Graft Rejection*/immunology , Graft Rejection*/diagnosis, Humans ; Immunosuppressive Agents/therapeutic use ; Acute Disease ; Plasmapheresis ; Biopsy
مستخلص: Purpose of Review: To review what is currently known about the pathogenesis, diagnosis, treatment, and prevention of acute rejection (AR) in lung transplantation.
Recent Findings: Epigenomic and transcriptomic methods are gaining traction as tools for earlier detection of AR, which still remains primarily a histopathologic diagnosis.
Summary: Acute rejection is a common cause of early posttransplant lung graft dysfunction and increases the risk of chronic rejection. Detection and diagnosis of AR is primarily based on histopathology, but noninvasive molecular methods are undergoing investigation. Two subtypes of AR exist: acute cellular rejection (ACR) and antibody-mediated rejection (AMR). Both can have varied clinical presentation, ranging from asymptomatic to fulminant ARDS, and can present simultaneously. Diagnosis of ACR requires transbronchial biopsy; AMR requires the additional measuring of circulating donor-specific antibody (DSA) levels. First-line treatment in ACR is increased immunosuppression (pulse-dose or tapered dose glucocorticoids); refractory cases may need antibody-based lymphodepletion therapy. First line treatment in AMR focuses on circulating DSA removal with B and plasma cell depletion; plasmapheresis, intravenous human immunoglobulin (IVIG), bortezomib, and rituximab are often employed.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment. A consensus report from the Pulmonary Council of the ISHLT. 2019 [cited 2024 Feb 4]. Available at: https://doi.org/10.1016/j.healun.2019.03.009 .
Parulekar AD, Kao CC. Detection, classification, and management of rejection after lung transplantation. J Thorac Dis 2019; 11: (Suppl 14): S1732–S1739.
Keller MB, Tian X, Jang MK, et al. Higher molecular injury at diagnosis of acute cellular rejection increases the risk of lung allograft failure. Am J Respir Crit Care Med 2024; doi: 10.1164/rccm.202305-0798OC. (PMID: 10.1164/rccm.202305-0798OC)
Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009; 6:54–65.
Todd JL, Neely ML, Kopetskie H, et al. Risk factors for acute rejection in the first year after lung transplant a multicenter study. Am J Respir Crit Care Med 2020; 202:576–585.
Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report. 2012 [cited 2024 Feb 4]. Available at: http://dx.doi.org/10.1016/j.healun.2012.08.004 .
Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transpl 2007; 26:1229–1271.
Dabbs ADV, Hoffman LA, Iacono AT, et al. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation? Heart Lung J Acute Crit Care 2004; 33:372–380.
Subramani MV, Pandit S, Gadre SK. Acute rejection and post lung transplant surveillance. Indian J Thorac Cardiovasc Surg 2022; 38: (Suppl 2): 271–279.
Greer M, Werlein C, Jonigk D. Surveillance for acute cellular rejection after lung transplantation. Ann Transl Med 2020; 8:410–1410.
Benzimra M. Surveillance bronchoscopy: is it still relevant? Semin Respir Crit Care Med 2018; 39:219–226.
Levine SM. A survey of clinical practice of lung transplantation in North America. Chest 2004; 125:1224–1238.
Penninga L, Penninga EI, Møller CH, et al. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev 2013; 5:CD008817.
Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001; 71:1772–1776.
Rudzik KN, Moore CA, Sacha LM, et al. Rabbit antithymocyte globulin for treatment of corticosteroid refractory acute cellular rejection after lung transplantation. Transplantation 2023; 107:1828–1834.
Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc 2009; 6:79–93.
Benzimra M, Calligaro GL, Glanville AR. Acute rejection. J Thorac Dis 2017; 9:5440–5457.
Bery AI, Hachem RR. Antibody-mediated rejection after lung transplantation. Ann Transl Med 2020; 8:411.
Hachem RR, Yusen RD, Meyers BF, et al. Anti-HLA antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29:973–980.
Kulkarni HS, Bemiss BC, Hachem RR. Antibody-mediated rejection in lung transplantation. Curr Transplant Rep 2015; 2:316–323.
Young KA, Ali HA, Beermann KJ, et al. Lung transplantation and the era of the sensitized patient. Front Immunol 2021; 12:689420.
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2016; 35:397–406.
Westall GP, Paraskeva MA, Snell GI. Antibody-mediated rejection. Curr Opin Organ Transplant 2015; 20:492–497.
Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation: a retrospective, single center, case series. J Heart Lung Transplant 2013; 32:1034–1040.
Sunder S, Witt C, Byers D, Hachem R. Risk factors for the development of antibody-mediated rejection (AMR) after lung transplantation. J Heart Lung Transplant 2019; 38: (Suppl): S408.
Wallace WD, Weigt SS, Farver CF. Update on pathology of antibody-mediated rejection in the lung allograft. Curr Opin Organ Transplant 2014; 19:303.
Roux A, Levine DJ, Zeevi A, et al. Banff lung report: current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR). Am J Transplant 2019; 19:21–31.
Magro CM, Pope Harman A, Klinger D, et al. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant 2003; 3:1143–1154.
Aguilar P, Carpenter D, Ritter J, et al. The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. Am J Transplant 2018; 18:936–944.
Roden AC, Maleszewski JJ, Yi ES, et al. Reproducibility of complement 4d deposition by immunofluorescence and immunohistochemistry in lung allograft biopsies. J Heart Lung Transplant 2014; 33:1223–1232.
Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272–283.
Neuhaus K, Hohlfelder B, Bollinger J, et al . Antibody-mediated rejection management following lung transplantation, 2022. [cited 2024 Mar 16]. Available at: https://journals.sagepub.com/doi/full/10.1177/10600280211012410 .
Timofeeva OA, Choe J, Alsammak M, et al. Guiding therapeutic plasma exchange for antibody-mediated rejection treatment in lung transplant recipients – a retrospective study. Transpl Int 2021; 34:700–708.
Xu Q, Elrefaei M, Taupin JL, et al. Chronic lung allograft dysfunction is associated with an increased number of non-HLA antibodies. J Heart Lung Transplant 2024; 43:663–672.
Tikkanen JM, Tinckam K. Intragraft donor-specific antibodies and lung transplantation. Eur Respir J 2019; 54:1901937.
Morrell MR, Pilewski JM, Gries CJ, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 2014; 33:1288–1294.
Keller M, Agbor-Enoh S. Cell-free DNA in lung transplantation: Research tool or clinical workhorse? Curr Opin Organ Transplant 2022; 27:177–183.
Li Y, Liang B. Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation. Front Immunol 2023; 14:1263389.
Trindade AJ, Chapin KC, Gray JN, et al. Relative change in donor-derived cell-free DNA is superior to absolute values for diagnosis of acute lung allograft dysfunction. Transplant Direct 2023; 9:E1487.
Bazemore K, Permpalung N, Mathew J, et al. Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunction. Am J Transplant 2022; 22:2560–2570.
Silva TD, Voisey J, Hopkins P, et al. Markers of rejection of a lung allograft: state of the art. Biomark Med 2022; 16:483–498.
Patil J, Lande JD, Li N, et al. Bronchoalveolar lavage cell gene expression in acute lung rejection: development of a diagnostic classifier. Transplantation 2008; 85:224–231.
Mirzakhani M, Mohammadnia-Afrouzi M, Shahbazi M, et al. The exosome as a novel predictive/diagnostic biomarker of rejection in the field of transplantation. Clin Immunol 2019; 203:134–141.
Gregson AL, Hoji A, Injean P, et al. Altered exosomal RNA profiles in bronchoalveolar lavage from lung transplants with acute rejection. Am J Respir Crit Care Med 2015; 192:1490–1503.
Kueckelhaus M, Fischer S, Lian CG, et al. Utility of sentinel flaps in assessing facial allograft rejection. Plast Reconstr Surg 2015; 135:250–258.
Gerlach UA, Vrakas G, Sawitzki B, et al. Abdominal wall transplantation: skin as a sentinel marker for rejection. Am J Transplant 2016; 16:1892–1900.
Haykal S, Juvet S, Chan AW, et al. Assessment of acute rejection in a lung transplant recipient using a sentinel skin flap. Transpl Int 2023; 36:11166.
المشرفين على المادة: 0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20240424 Date Completed: 20240523 Latest Revision: 20240604
رمز التحديث: 20240604
DOI: 10.1097/MCP.0000000000001078
PMID: 38656281
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-6971
DOI:10.1097/MCP.0000000000001078